GCF has funded Dr Amanda Ashley and her team at Auckland Hospital,three patients to go onto this valuable trial to the value of $23,741.

ACTICCA-1 is a randomised, controlled, two stage, multicentre Phase III trial comparing gemcitabine+ cisplatin with standard of care (capecitabine) after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma. Cholangiocarcinoma is diagnosed in approximately 80 people every year in New Zealand. In half of these people curative intent treatment with surgery is possible. Following this surgery however, only 20-30% of people survive 5 years. This long term survival can be increase by giving chemotherapy after the surgery and the current standard is capecitabine. In this trial patients will receive either cisplatin and gemcitabine or capecitabine alone following their surgery. The aim is to find out if giving cisplatin and gemcitabine can improve the outcomes for these patients.

Join the Gutsy Team to help save lives from Gut Cancers!

Get the family together and make it a great day.

Full Marathon
Half Marathon
12k Traverse
5k Challenge
2k Kids Marathon

Exercise helps prevent gut cancers!

Register today through here

TV interviews

View our latest TV interviews
TV 3  Newshub click  here

TV 3 AM show click here

TV 3 The Cafe show click here